3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
2
Neoplasm Metastasis
1
Lung Neoplasms
1
Castrate-Resistant Prostate Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Prednisone
54
Radiotherapy
52
Docetaxel
51
Leuprolide
48
Goserelin
47
bicalutamide
45
enzalutamide
30
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
27
Androgen Antagonists
27
Flutamide
24
Triptorelin Pamoate
22
apalutamide
19
Gonadotropin-Releasing Hormone
18
Abiraterone Acetate
18
abiraterone
16
Radiation
15
Zoledronic Acid
14
Magnetic Resonance Spectroscopy
13
gallium 68 PSMA-11
12
Prednisolone
11
luprolide acetate gel depot
10
darolutamide
10
cabazitaxel
9
Radiosurgery
9
Standard of Care
8
Specimen Handling
8
Radiotherapy, Intensity-Modulated
8
Radiotherapy, Conformal
8
Estramustine
8
Dexamethasone
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Prostatic Neoplasms
×
OGX-011
×
Clear all
NCT01188187
2016-10-14
SYNERGY
Achieve Life Sciences
Phase 3
Completed
1,022 enrolled
NCT01578655
2016-10-12
AFFINITY
Achieve Life Sciences
Phase 3
Completed
630 enrolled